OrbusNeich Starts China Trial Of COMBO Dual Therapy Stent
OrbusNeich, headquartered in Hong Kong, has enrolled the first patient in a China clinical trial of its COMBO™ Dual Therapy Stent. The COMBO stent has a coating of anti-CD34 antibodies to promote endothelialization of the stent, combined with sirolimus drug elution to deter the blood vessel from re-closing over the longer term. OrbusNeich, which makes medical devices for the vascular market, has manufacturing facilities in Shenzhen and the Netherlands, plus an R&D operation in Fort Lauderdale, Florida.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.